

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

**1. - 6. canceled**

**7. (currently amended):** A method for treating insufficiency of peripheral circulation or peripheral angiostenosis in a subject for which HGF is effective, comprising administering ~~intramuscularly at the affected site~~ to the area affected by said insufficiency of peripheral circulation or peripheral angiostenosis a therapeutically effective amount of an expression vector containing a constitutive promoter operably linked to a HGF coding sequence, whereby said HGF is expressed, promoting the growth of vascular endothelial cells but not vascular smooth muscle cells, thereby treating the insufficiency of peripheral circulation or peripheral angiostenosis.

**8. (previously presented):** The method of claim 7, wherein said expression vector is a non-viral expression vector containing a HGF coding sequence.

**9. (previously presented):** The method of claim 8, wherein said non-viral expression vector is encapsulated in a liposome.

**10. (previously presented):** The method of claim 9, wherein the membrane of said liposome is fused with attenuated Sendai virus particles.

**11. (previously presented):** The method of claim 7, wherein said expression vector is a viral expression vector containing a HGF coding sequence.